University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer

Simple item page
dc.contributor.authorHill, Andrew Graham
dc.contributor.authorFindlay, Michael
dc.contributor.authorBurge, Matthew
dc.contributor.authorJackson, Christopher
dc.contributor.authorGarcia Alfonso, Pilar
dc.contributor.authorSamuel, Leslie
dc.contributor.authorGanju, Vinod
dc.contributor.authorKarthaus, Meinolf
dc.contributor.authorAmatu, Alessio
dc.contributor.authorJeffrey, Mark
dc.contributor.authorDi Bartolomeo, Maria
dc.contributor.authorBridgewater, John
dc.contributor.authorCoveler, Andrew
dc.contributor.authorHidalgo, Manuel
dc.contributor.authorKapp, Amy
dc.contributor.authorSufan, Roxanna
dc.contributor.authorMcCall, Bruce
dc.contributor.authorHanley, William
dc.contributor.authorPenuel, Elicia
dc.contributor.authorPirzkall, Andrea
dc.contributor.authorTabernero, Josep
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.date.accessioned2019-03-05T00:02:54Z
dc.date.available2019-03-05T00:02:54Z
dc.date.embargoedUntil2019-03-05
dc.date.issued2018-05
dc.descriptionAcknowledgments The authors wish many thanks to all of the patients and the investigators who participated in this study. Writing assistance was provided by Genentech, Inc. This work was supported by Genentech, Inc. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.en
dc.description.statusPeer revieweden
dc.format.extent9
dc.format.extent2313146
dc.identifier117868149
dc.identifier15b13388-8603-47bf-b268-776002d0dc06
dc.identifier85047808210
dc.identifier.citationHill, A G, Findlay, M, Burge, M, Jackson, C, Garcia Alfonso, P, Samuel, L, Ganju, V, Karthaus, M, Amatu, A, Jeffrey, M, Di Bartolomeo, M, Bridgewater, J, Coveler, A, Hidalgo, M, Kapp, A, Sufan, R, McCall, B, Hanley, W, Penuel, E, Pirzkall, A & Tabernero, J 2018, 'Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer', Clinical Cancer Research, vol. 24, no. 10, pp. 2276-2284. https://doi.org/10.1158/1078-0432.CCR-17-0646en
dc.identifier.doi10.1158/1078-0432.CCR-17-0646
dc.identifier.iss10en
dc.identifier.issn1078-0432
dc.identifier.otherORCID: /0000-0002-8402-8670/work/50559793
dc.identifier.urihttp://hdl.handle.net/2164/11999
dc.identifier.vol24en
dc.language.isoeng
dc.relation.ispartofClinical Cancer Researchen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titlePhase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal canceren
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
AACR_Accepted_Manuscript.pdf
Size:
2.21 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.29 KB
Format:
Plain Text
Description:
Download

Collections

All research
Applied Health Sciences research
University Office research

The Sir Duncan Rice Library

University of Aberdeen

Bedford Road

Aberdeen

AB24 3AA


Tel: +44 (0)1224 273330

Email: library@abdn.ac.uk

Share and keep up to date


FacebookTwitterWordpress